We validated three new potent eIF4A inhibitors, RBF197, RBF 203, and RBF 208, which decreased diffuse large B-cell lymphoma (DLBCL) cell viability. The gene discussed is EIF4A1; the disease is diffuse large B-cell lymphoma.